Transparency Market Research Human Papillomavirus and Cytomegalovirus Therapeutics Market- Global Industry Analysis and Forecast 2014 – 2020
Published Date 2015-01-14
117 Page Report
Buy Now
Request Sample
Press Release
Human Papillomavirus and Cytomegalovirus Therapeutics Market Expected to Reach USD 2.34 Billion and 0.92 Billion Globally in 2020 Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Human Papillomavirus and Cytomegalovirus Therapeutics Market
REPORT DESCRIPTION
Human Papillomavirus and Cytomegalovirus Therapeutics Market- Global Industry Analysis and Forecast 2014 – 2020
According to a new market report published by Transparency Market Research “Human Papillomavirus and Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” the global human papillomavirus therapeutics market was valued at USD 1.40 billion in 2013 and is expected to grow at a CAGR of 7.7% from 2014 to 2020, to reach an estimated value of USD 2.34 billion in 2020. The global cytomegalovirus therapeutics market was valued at USD 0.87 billion in 2013 and is expected to grow at a CAGR of 1.5% from 2014 to 2020, to reach an estimated value of USD 0.92 billion in 2020.
Human papillomavirus (HPV) and Cytomegalovirus (CMV) are DNA viruses that cause serious health conditions in patients of all ages. HPV is one of the most common sexually transferred viruses causing genital infections and cancers. CMV is an opportunistic pathogen affecting immunocompromised patients; thus transplant and HIV patients are at high risk of acquiring CMV infections. Human papillomaviruses are a group of more than 100 virus strains, of which certain types of viruses lead to warts or papillomas progressing into benign or malignant tumors. More than 40 HPV strains are sexually transferred affecting genital, anal and oral regions. The categorization of HPV strains is done on the basis of risk, i.e. high-risk and low-risk; where highrisk viruses are oncogenic type and low-risk viruses are not associated with cancer. According to CDC, in 2012, an estimated 20 million persons were infected in the U.S., and an estimated 6.2 million new HPV infections were expected to occur annually. HPV infection is common among adolescents and young adults, with prevalence among adolescent girls as high as 64%.
Browse the full Human Papillomavirus and Cytomegalovirus Therapeutics Market Report at : http://www.transparencymarketresearch.com/hpv-cmv-therapeutics-market.html
Transparency Market Research
2
Human Papillomavirus and Cytomegalovirus Therapeutics Market
Cytomegalovirus infections are usually dormant in healthy individuals; however, the virus stays in the human body for a long time. The virus is easily transmitted through body fluids such as saliva, semen, blood, breast milk and urine. Due to these reasons the virus has spread rapidly through a large population across the globe. Epidemiological studies conducted in various parts of the world report that the seroprevalence of CMV is high in low and middle income countries, and ranges from 50% in certain parts of U.S. and Europe to over 95% in Asia Pacific and South American countries.
Get Free Sample Report Human Papillomavirus and Cytomegalovirus Therapeutics Market : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3986
Immunomodulators was the largest drug class by revenue share of the HPV therapeutics market in 2013 due to its high efficiency, cost-effectiveness and non-invasive nature of treatment. In the same year, the genital warts segment accounted for the largest market share in HPV therapeutic applications market and is expected to continue to remain a major application of HPV therapeutics, due to its growing prevalence in emerging economies of the world. Ganciclovir and valganciclovir are the first line drugs prescribed for any CMV infection. Valcyte (valganciclovir) by Roche, a prodrug of ganciclovir, is the only branded drug in the market which is expected to lose its exclusivity in March 2015, while pediatric exclusivity will last till September 2015. Thus, ganciclovir and valganciclovir accounted for a major market share in 2013. Retinitis was observed to be the most common complication of CMV infection in HIV patients. Hence, in 2013 retinitis was the largest application segment in CMV therapeutics market.
Browse the full Human Papillomavirus and Cytomegalovirus Therapeutics Market at : http://www.transparencymarketresearch.com/pressrelease/hpv-cmv-therapeutics-market.htm
Transparency Market Research
3
Human Papillomavirus and Cytomegalovirus Therapeutics Market
North American HPV therapeutics market was observed to be the largest market by revenue share due to major driving factors such as rising diagnostic rate, increase in sexually active population, and rising international migration. Moreover, CMV therapeutics market in North America is primarily driven by rise in organ transplant operations, high drug costs and sexually transmitted disease (STD) -triggering sexual lifestyle. Asia-Pacific and South America are anticipated to witness substantial growth in the HPV and CMV therapeutics market. HPV therapeutics market in these geographies will be driven by increasing prevalence of HPV infections, improving economical dynamics, changing sexual lifestyles, and government support to create awareness regarding STDs. CMV therapeutics market in Asia-Pacific and South America is growing due to major market drivers such as high prevalence of HIV infection and increasing number of transplant procedures due to developing economic conditions.
In the HPV therapeutics market, Valeant Pharmaceuticals International, Inc. accounted for a major market share in 2013 with its leading brands such as Aldara (Imiquimod 5%), Zyclara(Imiquimod 3.75%),, Efudex (5-Fluorouracil 5%) and Carac (5-Fluorouracil 0.5%). The other key players in the global HPV therapeutics market are Fougera Pharmaceuticals, Inc., Perrigo Company plc, Taro Pharmaceutical Industries, Ltd., Merck & Co., among others. Roche AG dominated the global CMV therapeutics market in 2013, owing to its Valcyte being the only branded formulation in the market. The other key players in the global CMV therapeutics market are Clinigen Group plc, Gilead Sciences, Ranbaxy Laboratories, Ltd., and Fresenius Kabi USA among others.
The global HPV and CMV therapeutics market is segmented as follows:
HPV Therapeutics Market
ďƒ˜ HPV Therapeutics Market, by Drug Class
ďƒ˜ Immunomodulators
Transparency Market Research
4
Human Papillomavirus and Cytomegalovirus Therapeutics Market
Keratolytic Agents
Antineoplastic Agents
Sinecatechins
HPV Therapeutics Market, by Application
Genital Warts
Genital Cancer
Epidermodyplasia verruciformis
Oral Papillomas
Others (Oropharyngeal cancer, laryngeal papillomatosis and others)
HPV Therapeutics Market, Pipeline Analysis
Transparency Market Research
5
Human Papillomavirus and Cytomegalovirus Therapeutics Market
Early Stage (Preclinical, Phase I and Phase II) Drug Candidates
Late Stage (Phase III) Drug Candidates.
CMV Therapeutics Market
CMV Therapeutics Market, by Major Antiviral Drugs
Ganciclovir/ Valganciclovir
Foscarnet
Cidofovir
CMV Therapeutics Market, by Application
Retinitis
Pneumonia
Transparency Market Research
6
Human Papillomavirus and Cytomegalovirus Therapeutics Market
Gastrointestinal ulcers
Encephalitis
Others (Mouth ulcers, Diarrhea, Pharyngitis and others)
CMV Therapeutics Market, Pipeline Analysis
Early Stage (Preclinical, Phase I and Phase II) Drug Candidates
Late Stage (Phase III) Drug Candidates
HPV and CMV Therapeutics Market, By Geography
North America
Europe
Asia-Pacific
South America
Transparency Market Research
7
Human Papillomavirus and Cytomegalovirus Therapeutics Market
ďƒ˜ Rest of the World (RoW) TABLE OF CONTENT
Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 Assumptions 1.5 List of Abbreviations
Chapter 2 Executive Summary 2.1 Market Snapshot: Global HPV Therapeutics Market 2.2 Market Snapshot: Global CMV Therapeutics Market 2.3 Global HPV and CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Chapter 3 Global HPV and CMV Therapeutics Market Overview 3.1 Market Definition and Overview 3.2 Market Dynamics 3.2.1 Human Papillomavirus (HPV) Therapeutics Market
Transparency Market Research
8
Human Papillomavirus and Cytomegalovirus Therapeutics Market
3.2.1.1 Drivers 3.2.1.1.1 Increasing prevalence of HPV infections in developing and underdeveloped economies is aiding the market growth 3.2.1.1.2 Global Age-specific incidence of cervical cancer 3.2.1.1.3 Severe side-effects of HPV vaccines are restraining the market growth and creating opportunity for therapeutics market 3.2.1.2 Restraints 3.2.1.2.1 Increasing demand for minimally invasive surgical procedures in genital warts treatment 3.2.1.2.2 Lack of awareness in developing areas is declining the diagnostic rates 3.2.1.2.2.1 Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions (estimations for 2012) 3.2.1.3 Opportunities 3.2.1.3.1 Opportunity for biologics and drugs with low toxicity and short treatment regime against HPV infections 3.2.1.3.2 Health issues raised against approved vaccines have provided wide range of opportunities for effective and safe vaccines and therapeutics 3.2.2 Cytomegalovirus Therapeutics Market 3.2.2.1 Drivers 3.2.2.1.1 High seroprevalence adding to patient pool for CMV therapeutics market 3.2.2.1.2 High global demand for low-cost generic drugs, especially in low- and middleincome countries in South Latin America and Asia Pacific
Transparency Market Research
9
Human Papillomavirus and Cytomegalovirus Therapeutics Market
3.2.2.2 Restraints 3.2.2.2.1 Decreasing CMV prevalence due to highly actively antiretroviral therapy (HAART) and decreasing transplant procedures 3.2.2.3 Opportunities 3.2.2.3.1 Less competition in pediatric CMV therapeutics and increasing demand for CMV vaccine 3.3 Value Chain Analysis 3.4 HPV Vaccines : Current Global Scenario 3.5 HPV Drug Treatment Regime Analysis: Length of HPV Drug treatment (No. of days) 3.6 HPV Surgery Treatment: Type of Surgery and Average Cost (USD) 3.7 Pricing Analysis 3.7.1 Pricing Analysis: HPV Therapeutics Market 3.7.2 Pricing Analysis: CMV Therapeutics Market 3.7.3 HPV Treatment Cost Analysis 3.7.4 CMV Treatment Cost Analysis 3.8 Porter’s Five Forces Analysis: Global HPV & CMV Therapeutics Market 3.8.1 Bargaining Power of Suppliers 3.8.2 Bargaining Power of Buyers 3.8.3 Threat of Substitutes 3.8.4 Threat of New Entrants
Transparency Market Research
10
Human Papillomavirus and Cytomegalovirus Therapeutics Market
3.8.5 Competitive Rivalry 3.9 Market Attractiveness Analysis, by Geography, 2013 3.9.1 HPV Therapeutics Market Attractiveness Analysis, Geography, 2013 3.9.2 CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013 3.10 Market Share Analysis, by Key Players, 2013 (Value %) 3.10.1 HPV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %) 3.10.2 CMV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %)
Chapter 4 Global HPV Therapeutics Market 4.1 Overview 4.2 HPV Therapeutics Market, by Drug Class 4.2.1 Overview 4.2.1.1 Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD Million) 4.2.2 Immunomodulators 4.2.2.1 Global Immunomodulators Market Revenue, 2012 – 2020 (USD Million) 4.2.3 Keratolytic Agents 4.2.3.1 Global Keratolytic Agents Market Revenue, 2012 – 2020 (USD Million) 4.2.4 Anti-neoplastic Agents 4.2.4.1 Global Anti-neoplastic Agents Market Revenue, 2012 – 2020 (USD Million)
Transparency Market Research
11
Human Papillomavirus and Cytomegalovirus Therapeutics Market
4.2.5 Sinecatechins 4.2.5.1 Global Sinecatechins Market Revenue, 2012 – 2020 (USD Million) 4.3 HPV Therapeutics Market, by Application 4.3.1 Overview 4.3.1.1 Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million) 4.3.2 Genital Warts 4.3.2.1 Global Genital Warts HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million) 4.3.3 Genital Cancer 4.3.3.1 Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) 4.3.4 Epidermodysplasia Verruciformis 4.3.4.1 Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) 4.3.5 Oral Papillomas 4.3.5.1 Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) 4.3.6 Others (Oropharyngeal cancer, laryngeal papillomatosis and others) 4.3.6.1 Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) 4.4 HPV Therapeutics Market, Pipeline Analysis 4.4.1 HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates 4.4.2 HPV Therapeutics: Late Stage (Phase III) Drug Candidates
Transparency Market Research
12
Human Papillomavirus and Cytomegalovirus Therapeutics Market
Chapter 5 Global Cytomegalovirus Therapeutics Market 5.1 Introduction 5.1.1 Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million) 5.2 CMV Therapeutics Market, by Major Antiviral Drugs 5.2.1 Overview 5.2.1.1 Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million) 5.2.2 Ganciclovir/Valganciclovir 5.2.2.1 Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million) 5.2.3 Foscarnet 5.2.3.1 Global Foscarnet Market Revenue, 2012 - 2020 (USD Million) 5.2.4 Cidofovir 5.2.4.1 Global Cidofovir Market Revenue, 2012 - 2020 (USD Million) 5.3 CMV Therapeutics Market, by Applications 5.3.1 Overview 5.3.1.1 Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million) 5.3.2 CMV Retinitis 5.3.2.1 Global CMV Retinitis Therapeutics Market Revenue,2012 - 2020 (USD Million) 5.3.3 Pneumonia
Transparency Market Research
13
Human Papillomavirus and Cytomegalovirus Therapeutics Market
5.3.3.1 Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million) 5.3.4 Gastrointestinal ulcers 5.3.4.1 Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD Million) 5.3.5 Encephalitis 5.3.5.1 Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million) 5.3.6 Others (Mouth ulcers, pharyngitis) 5.3.6.1 Global Other (Mouth ulcers, Pharyngitis)CMV Therapeutics Market Revenue,2012 - 2020 (USD Million) 5.4 CMV Therapeutics Market, Pipeline Analysis 5.4.1 CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates 5.4.2 CMV Therapeutics: Late Stage (Phase III) Drug Candidates 5.4.2.1 Introduction 5.4.2.1.1 MK8228/ letermovir/AIC246 5.4.2.1.1.1 Global Letermovir Market Revenue, 2018 - 2020 (USD Million) 5.4.2.1.2 Brincidofovir/CMX001 5.4.2.1.2.1 Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million)
Chapter 6 Global HPV and CMV Therapeutics Market, by Geography 6.1 Overview
Transparency Market Research
14
Human Papillomavirus and Cytomegalovirus Therapeutics Market
6.1.1 Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million) 6.1.1.1 Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million) 6.2 North America 6.2.1 North America HPV Therapeutics Market 6.2.1.1 North America HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million) 6.2.2 North America CMV Therapeutics Market 6.2.2.1 North America CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million) 6.3 Europe 6.3.1 Europe HPV Therapeutics Market 6.3.1.1 Europe HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million) 6.3.2 Europe CMV Therapeutics Market 6.3.2.1 Europe CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million) 6.4 Asia Pacific 6.4.1 Asia Pacific HPV Therapeutics Market 6.4.1.1 Asia Pacific HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million) 6.4.2 Asia Pacific CMV Therapeutics Market 6.4.2.1 Asia Pacific CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million) 6.5 South America 6.5.1 South America HPV Therapeutics Market 6.5.1.1 South America HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Transparency Market Research
15
Human Papillomavirus and Cytomegalovirus Therapeutics Market
6.5.2 South America CMV Therapeutics Market 6.5.2.1 South America CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million) 6.6 Rest of the World 6.6.1 Rest of the World HPV Therapeutics Market 6.6.1.1 Rest of the World HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million) 6.6.2 Rest of the World CMV Therapeutics Market 6.6.2.1 Rest of the World CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Chapter 7 Recommendations 7.1.1 Market avails wide scope for new molecules as most of the first line drugs have been off patented 7.1.2 Building stronger market hold in Africa
Chapter 8 Company Profiles 8.1 AbbVie, Inc. 8.1.1 Company Overview 8.1.2 Financial Overview 8.1.3 Product Portfolio 8.1.4 Business Strategies 8.1.4.1 Strategic Collaborations and Agreements
Transparency Market Research
16
Human Papillomavirus and Cytomegalovirus Therapeutics Market
8.1.5 Mergers and Acquisitions 8.1.6 Recent Developments 8.2 Actavis plc 8.2.1 Company Overview 8.2.2 Financial Overview 8.2.3 Product Portfolio 8.2.4 Business Strategies 8.2.4.1 Mergers and acquisitions 8.2.4.2 Extensive R&D practices 8.2.4.3 Strategic collaborations 8.2.5 Recent Developments 8.3 Clinigen Group plc 8.3.1 Company Overview 8.3.2 Financial Overview 8.3.3 Product Portfolio 8.3.4 Business Strategies 8.3.4.1 Mergers and Acquisitions 8.3.5 Recent Developments 8.4 Merck & Co., Inc. 8.4.1 Company Overview
Transparency Market Research
17
Human Papillomavirus and Cytomegalovirus Therapeutics Market
8.4.2 Financial Overview 8.4.3 Product Portfolio 8.4.4 Business Strategies 8.4.4.1 Mergers and acquisitions 8.4.4.2 Strategic collaborations 8.4.4.3 Expansion in emerging markets 8.4.5 Recent Developments 8.5 Perrigo Company plc 8.5.1 Company Overview 8.5.2 Financial Overview 8.5.3 Product Portfolio 8.5.4 Business Strategies 8.5.5 Mergers and Acquisitions 8.5.6 Recent Developments 8.6 Roche Holdings AG 8.6.1 Company Overview 8.6.2 Financial Overview 8.6.3 Product Portfolio 8.6.4 Business Strategies 8.6.4.1 Consistent product launches
Transparency Market Research
18
Human Papillomavirus and Cytomegalovirus Therapeutics Market
8.6.4.2 Mergers and Acquisitions 8.6.5 Recent Developments 8.7 Valeant Pharmaceuticals International, Inc. 8.7.1 Company Overview 8.7.2 Financial Overview 8.7.3 Product Portfolio 8.7.4 Business Strategies 8.7.4.1 Mergers and acquisitions 8.7.5 Recent Developments List of Figures
FIG. 1 HPV Therapeutics: Market Segmentation FIG. 2 CMV Therapeutics: Market Segmentation FIG. 3 Global HPV and CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million) FIG. 4 Global Age-specific incidence of cervical cancer FIG. 5 Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions and five continents (estimations for 2012) FIG. 6 Heat Map Analysis: Immunization Array of Currently Marketed Vaccines by Major Countries FIG. 7 Global Human Immunodeficiency Virus (HIV) Prevalence, 1990 - 2008 FIG. 8 U.S. Transplant Procedures, 2000 - 2013
Transparency Market Research
19
Human Papillomavirus and Cytomegalovirus Therapeutics Market
FIG. 9 Global HPV and CMV Therapeutics Market, Value Chain Analysis FIG. 10 Porter’s Five Forces Analysis for the Global HPV & CMV Therapeutics Market FIG. 11 HPV Therapeutics Market Attractiveness Analysis: by Geography, 2013 FIG. 12 CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013 FIG. 13 HPV Therapeutics Market Share Analysis: by Key Players, 2013 (Value %) FIG. 14 CMV Therapeutics Market Attractiveness Analysis: by Key Players, 2013 (Value %) FIG. 15 Global Immunomodulators Market Revenue, 2012 – 2020 (USD Million) FIG. 16 Global Keratolytic Agents Market Revenue, 2012 – 2020 (USD Million) FIG. 17 Global Anti-neoplastic Agents Market Revenue, 2012 – 2020 (USD Million) FIG. 18 Global Sinecatechins Market Revenue, 2012 – 2020 (USD Million) FIG. 19 Global Genital Warts HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million) FIG. 20 Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 21 Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 22 Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 23 Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 24 Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million) FIG. 25 Global Foscarnet Market Revenue, 2012 - 2020 (USD Million) FIG. 26 Global Cidofovir Market Revenue, 2012 - 2020 (USD Million)
Transparency Market Research
20
Human Papillomavirus and Cytomegalovirus Therapeutics Market
FIG. 27 Global CMV Retinitis Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 28 Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 29 Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 30 Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 31 Global Other (Mouth ulcers, Pharyngitis) CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 32 Global Letermovir Market Revenue, 2018 - 2020 (USD Million) FIG. 33 Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million) FIG. 34 North America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 35 North America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 36 Europe HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 37 Europe CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 38 Asia Pacific HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 39 Asia Pacific CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 40 South America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 41 South America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 42 Rest of the World HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 43 Rest of the World CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million) FIG. 44 Tuberculosis Cases in Africa, 1996 – 2010 (‘000) FIG. 45 AbbVie, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
Transparency Market Research
21
Human Papillomavirus and Cytomegalovirus Therapeutics Market
FIG. 46 Actavis Inc.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 47 Clinigen Group plc: Annual Revenue, 2011 – 2013 (USD Million) FIG. 48 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 49 Perrigo Company plc: Annual Revenue: 2011 – 2013 (USD Million) FIG. 50 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million) FIG. 51 Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
List of Tables TABLE 1 Market Snapshot: Global HPV Therapeutics Market TABLE 2 Market Snapshot: Global CMV Therapeutics Market TABLE 3 HPV Vaccines Sales Track TABLE 4 Pricing Analysis: HPV Therapeutics Market TABLE 5 Pricing Analysis: CMV Therapeutics Market TABLE 6 HPV Strains and Diseases TABLE 7 Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD Million) TABLE 8 Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million) TABLE 9 HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates TABLE 10 Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million) TABLE 11 Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million)
Transparency Market Research
22
Human Papillomavirus and Cytomegalovirus Therapeutics Market
TABLE 12 Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million) TABLE 13 CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates TABLE 14 Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million) TABLE 15 Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million) Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com
Transparency Market Research
23
Human Papillomavirus and Cytomegalovirus Therapeutics Market
Website: http://www.transparencymarketresearch.com/ Browse The Market Research Blog : http://researchandreports.wordpress.com/ http://www.transparencymarketresearch.com
Transparency Market Research
24